Bellizzi AM. Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you? Hum Pathol. 2020;96:8-33. PMID: 31857137; PMCID: PMC7177196.

Bellizzi AM. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am. 2020;29:185-208. PubMed PMID: 32151355; PMCID: PMC7212902.

Bellizzi AM. An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin. Adv Anat Pathol. 2020;27:114-63. PubMed PMID: 32205473. PMC7700753

Gallicchio L, Elena JW, Fagan S, Carter M, Hamilton AS, Hastert T, Hunter L, Li J, Lynch CF, Milam J, Millar MM, Modjeski D, Paddock LE, Reed AR, Moses LB, Stroup AM, Sweeney C, Trapido EJ, West MM, Wu XC, Helzlsouer KJ.  Utilizing SEER for population-based cancer survivor epidemiologic studies: a feasibility study. Cancer Epidemiology, Biomarkers & Prevention 2020 .Sep;29(9):1699-1709. PMID:32651214; PMC7484198

Yuan Y, Van Dyke AL, Petkov VI, Hussey S, Moravec R, Altekruse SF, Sandoval M, Cress RD, Mueller LM, Mogi A, Hernandez BY, Selk FR, Lynch CF, Tucker TC, Lynch MA, Lefante C, Wu XC, Bateman C, Sweeney C, Doherty JA, Penberthy LS.  Pathology laboratory policies and procedures for releasing diagnostic tissue for molecular cancer research. Archives of Pathology & Laboratory Medicine 2020 Jun 4.  PMID:32496836.